Skip to main content

Peer Review reports

From: Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE

Original Submission
30 Apr 2018 Submitted Original manuscript
9 Jul 2018 Author responded Author comments - Jai Perumal
Resubmission - Version 2
9 Jul 2018 Submitted Manuscript version 2
4 Aug 2018 Reviewed Reviewer Report - Ali Manouchehrinia
10 Aug 2018 Reviewed Reviewer Report - Carmen Tur
20 Aug 2018 Reviewed Reviewer Report - Laure Michel
1 Feb 2019 Author responded Author comments - Jai Perumal
Resubmission - Version 3
1 Feb 2019 Submitted Manuscript version 3
17 Feb 2019 Reviewed Reviewer Report - Carmen Tur
23 Feb 2019 Reviewed Reviewer Report - Ali Manouchehrinia
2 May 2019 Author responded Author comments - Jai Perumal
Resubmission - Version 4
2 May 2019 Submitted Manuscript version 4
Publishing
20 May 2019 Editorially accepted
8 Jun 2019 Article published 10.1186/s12883-019-1337-z

You can find further information about peer review here.

Back to article page